Welcome to the Gastrointestinal (GI) Cancer Drug Development Summit - The only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies, ADCs, and precision oncology to address the large unmet clinical need in GI cancers.
Explore the full conference guide here: https://ter.li/rkdp17
This industry-dedicated meeting offers a comprehensive insight into developing optimal clinical programs for targeted, immune, and ADC therapies in these solid tumors. Join us and our 32+ expert speaker faculty as we navigate cancer heterogeneity and develop biomarker-driven enrichment strategies to direct better treatments to specific patient subsets and invest in rationale therapeutic combination approaches for this vastly unmet clinical need.
Whether your group is targeting microsatellite instable (MSI) and stable (MSS) CRC, a rare GI malignancy or treatment-resistant HCC, this unique forum is your opportunity to establish clinical collaborations, plan new combinatorial studies and assess how a future drug candidate can change the clinical landscape.
To learn more view our complete event guide: https://ter.li/rkdp17
Time: 08:30 to 17:00
Drug Developer: Full Access: Conference + Workshop + Focus Day early bird sale (save $1,100): USD 2196.00,
Drug Developer: Conference + Focus Day Early bird sale (save $900): USD 1997.00,
Drug Developer: Conference + 1 Workshop: early bird sale (save $700): USD 1798.00,
Drug Developer: Conference only Early bird sale (save $500): USD 1599.00,
Standard Pricing: Full Access: Conference + Workshop + Focus Day: early bird sale (save $1,400): USD 2796.00,
Standard pricing: Conference + Focus Day: early bird sale (save $1,100): USD 2497.00,
Standard pricing: Conference + 1 Workshop: early bird sale (save $900): USD 2198.00,
Standard pricing: Conference Only: early bird pricing (save $700): USD 1899.00
Speakers: Edward Cha, Global Development Lead, GI CANCERS and COMBINATIONS, Genentech, Giovanni Abbedessa, Global Head of Oncology Early Development, and Global Project Head, peg-IL-2 (THOR-707 / SAR444245), Sanofi Genzyme, Eric Murphy, Co-Founder and Chief Scientific Officer, Kinnate Biopharma Inc., Linh Alejandro, Adagrasib GI Medical Lead, Mirati Therapeutics, Valerie Jansen, Vice President - Clinical Development, Elevation Oncology, Tim Demuth, Vice President and Head of Global Clinical Development Oncology, Merck KGaA, Jian Chen, Director - Translational Research, Sandhill Therapeutics , Harish Dave, Co-Founder and Chief Medical Officer, AUM Biosciences , Shane Olwill, Senior Vice President and Head of Translational Science, Pieris Pharmaceuticals AG, Reva Basho, Medical Oncologist, Cedars-Sinai Medical Center, Brian Tunquist, Director, Companion Diagnostics, Pfizer, Timothy Chen, Director - Discovery and Cell Biology, Maverick Therapeutics, Hiranmayi Ravichandran, Mass Cytometry Specialist and Research Associate, Weill Cornell Medical College, Xing-Jian Lou, Program Director, National Cancer Institute, Afsaneh Barzi, Associate Professor of Medical Oncology, City of Hope-Director of Employer Health, Access-Hope, Chief Medical Advisor, Cardiff Oncology , Jeroen Lammerts Van Bueren, Senior Director - Translational Science, Merus NV, Roxana Schillaci, Senior Researcher, Instituto de Biología y Medicina Experimental, Buenos Aires (IBYME), Mallika Singh, VP, Translational Research, Revolution Medicines, Nataliya Uboha, Assistant Professor, University of Wisconsin-Madison, Volker Schellenberger, President and Chief Executive Officer, Amunix Pharmaceuticals Inc., Lauren Leiman, Executive Director, BloodPAC, Angelica Loskog, Chief Executive Officer, Lokon Pharma AB, Ting Xu, Chairman, Chief Executive Offier, Executive Director and Founder, Alphamab Oncology, Jason Christiansen, Chief Technology Officer, Boundless Bio, Laura Davison, Research Scientist, TeneoBio, Thomas Tan, Chief Scientific Officer, Bicara Therapuetics, Muhammad Shaalan Beg, Associate Professor and Assistant Director - Gastrointestinal Medical and Oncology, Internal Medicine, Gastrointestinal Co-Leader, UT Southwestern, Elizabeth Smyth, Clinical Consultant, Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Berke Olcaysoy, Molecular Biologist, Acibadem Healthcare Group, Benny Johnson, Assistant Professor- Gastrointestinal and Medical Oncology, MD Anderson Cancer Center, Kamala K Maddali, President and Founder, Health Collaborations LLC